Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alfasigma S.p.A.
Travere Looks Ahead To Phase III In Homocystinuria
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.
Sparsentan Fails In Phase III FSGS Study, But Travere Assessing Path To Approval
Travere’s drug, approved as Filspari for immunoglobulin A nephropathy, missed its eGFR primary endpoints in focal segmental glomerulosclerosis but showed meaningful improvement in proteinuria.
Calliditas Eyes Full Approval For Tarpeyo In IgAN After Positive Pivotal Update
Data from part B of the Swedish firm’s pivotal trial of Tarpeyo in the rare kidney disorder showed that the treatment effects lasted two years across the entire population, enabling the move from conditional to full approvals in several markets.
Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
- Other Names / Subsidiaries
- Defiante Farmaceutica S.A.
- Sigma-Tau Pharma Ltd
- Sigma-Tau Arzneimittel GmbH
- Sigma-Tau Research Switzerland SA
- Biofutura Pharma S.p.A.
- Alfa Wassermann SpA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.